Data from clinical studies, cell culture, and animal models implicate the uPA/uPAR/Plasminogen system in the development of atherosclerosis and aneurysms. However, the mechanisms through which uPA/uPAR/Plasminogen stimulate these diseases are not yet defined.
Data from clinical studies, cell culture, and animal models implicate the uPA/uPAR/Plasminogen system in the development of atherosclerosis and aneurysms. However, the mechanisms through which uPA/uPAR/Plasminogen stimulate these diseases are not yet defined.
We used genetically modified, atherosclerosis-prone mice, including mice with macrophage-specific uPA overexpression and mice genetically deficient in uPAR to elucidate mechanisms of uPA/uPAR/Plasminogen-accelerated atherosclerosis and aneurysm formation. We found that macrophage-specific uPA overexpression accelerates atherosclerosis and causes aortic root dilation in fat-fed Ldlr -/-mice (as we previously reported in Apoe -/-mice). Macrophage-expressed uPA accelerates atherosclerosis by stimulation of lesion progression rather than initiation, and causes disproportionate lipid accumulation in early lesions. uPA-accelerated atherosclerosis and aortic dilation are largely-if not completelyindependent of uPAR. In the absence of uPA overexpression, however, uPAR contributes modestly to both atherosclerosis and aortic dilation. Microarray studies identified S100A8 and S100A9 mRNA as the most highly upregulated transcripts in uPA-overexpressing macrophages; upregulation of S100A9 protein in uPA-overexpressing macrophages was confirmed by Western blotting. S100A8/A9, which are atherogenic in mice and are expressed in human atherosclerotic plaques, are also upregulated in aortae of mice with uPA-overexpressing macrophages, and macrophage S100A9 mRNA is upregulated by exposure of wild-type macrophages to medium from uPA-overexpressing macrophages.
Macrophage microarray data suggest significant effects of uPA overexpression on cell migration and cell-matrix interactions. Our results confirm-in a second animal modelthat macrophage-expressed uPA stimulates atherosclerosis and aortic dilation. They also reveal uPAR-independence of these actions, and implicate specific pathways in uPA/Plgaccelerated atherosclerosis and aneurysmal disease.
Atherosclerosis and aneurysm formation are common cardiovascular diseases that have a significant impact on human health. Atherosclerosis is characterized by accumulation, in the inner blood vessel wall, of cellular and matrix-rich plaques that cause vessel lumen narrowing and tissue ischemia. Clinical events in patients with atherosclerosis (e.g., heart attacks and strokes) are typically caused by rupture of atherosclerotic plaques with superimposed thrombosis that occludes the vessel lumen (1) . In contrast, aneurysms are abnormal expansions of a blood vessel that can lead to complete disruption of the vessel wall, causing sudden death (2) . The molecular mechanisms that contribute to plaque growth, plaque rupture, and aneurysm formation are incompletely understood. Elucidation of these mechanisms should enable the development of novel, targeted therapies that improve human health.
We and others (3) have hypothesized that the urokinase plasminogen activator (uPA)/plasminogen (Plg) system contributes to plaque growth, plaque rupture, and aneurysm formation.
This hypothesis is supported by observational human studies showing that uPA (expressed primarily by macrophages) and its cellsurface receptor uPAR (expressed by several vascular cell types) are present in human atherosclerotic lesions, with expression of both molecules correlated with lesion severity (4) (5) (6) (7) . Moreover, patients with evidence of increased Plg activation have an elevated risk for accelerated atherosclerosis and major cardiovascular events (8) (9) (10) ; and uPA expression is elevated in aneurysmal human aortae (11, 12) . Important roles for uPA in atherosclerosis and aneurysm formation are supported by recent studies in our laboratory showing that 15-wk-old Apoe -/-mice with macrophage-targeted uPA overexpression (SR-uPA +/0 mice, with scavenger receptor promoter-driven expression of a uPA transgene) have significantly accelerated plaque growth and aneurysm formation (13) (14) (15) , older SR-uPA
Apoe
-/-mice have increased atherosclerotic plaque rupture (16) , and recipients of bone marrow transplants from uPA null mice have less atherosclerosis than recipients of bone marrow from uPA-expressing mice (14) .
These mouse experiments strongly support the hypothesis that elevated uPA expression by artery wall macrophages accelerates atherosclerosis and aneurysm formation. We also showed, using Plg -/-mice, that accelerated atherosclerosis and aortic dilation in SR-uPA mice were mediated by uPA activation of Plg (15) .
However, our experiments also raise several issues. First, the role of uPAR in production of these phenotypes, acting either to facilitate uPA-mediated cell surface Plg activation (17) or independently of Plg activation (18) , remains unclear and cannot be addressed definitively in Apoe -/-mice because Plaur and Apoe are linked on mouse chromosome 7 (data not shown). Second, it is unknown whether uPA-accelerated atherosclerosis and aneurysm formation are confined to the Apoe -/-mouse model, an experimental setting that, while informative, is potentially limited by large differences in lipoprotein profiles compared to those of humans and by complete absence of apo E, a protein with diverse biological roles (19) (20) (21) 
Experimental Procedures
Mice and atherosclerosis studies-Apolipoprotein (apo) E-null mice (22) with macrophage-specific overexpression of uPA (i.e., SR-uPA
mice, in which the human scavenger receptor-A promoter drives expression of a mouse uPA transgene) were generated in our laboratory (13 (13) . Aortic roots were processed into OCT medium and aortae pinned and stained with Sudan IV (13, 14) . OCT blocks were sectioned (10 m thickness) and sections were stained with hematoxylin and eosin (H&E), oil red O, and the macrophage-specific antibodies MOMA-2 (Biosource) or Mac-2 (Cedarlane Labs) (13, 14) . For each stain, a total of 5 -7 sections per mouse (at 50-m steps) were analyzed. Observers blinded to genotype used image analysis software (ImagePro) to analyze digital images of histologic sections and pinned aortae.
Aortic root atherosclerosis was quantified by measuring intimal area. Oil red O-, MOMA-2, and Mac-2 areas were measured using color thresholding and planimetry, and the percentage of stained intimal area was calculated by dividing the stained area by the total intimal area measured on an adjacent section. Total and percentage of Sudan IVpositive aortic surface area were measured similarly.
We also counted the number of individual lesions on the surface of pinned aortae of 15-wk-old mice. Lesions were counted by two independent observers, using a dissecting microscope. The observers' counts were highly correlated (r 2 = 0.8) and the mean of their counts was used as the final determination. Aortic root circumference was measured at the level of the internal elastic lamina (IEL).
The maximal percent luminal stenoses of proximal coronary artery segments were calculated using measurements made on oil red O-stained sections (13) .
Measurement of plasma lipids, serum chemistries, peripheral blood counts, and uPA antigenPlasma obtained by retro-orbital bleed after a 4-hr fast was used for measurement of total cholesterol and triglycerides (13) . Plasma lipoproteins were also analyzed by fast protein liquid chromatography (FPLC) (13) . Plasma LDL and HDL were determined by measuring cholesterol in the respective pooled FPLC fractions. Retroorbital blood drawn at 8 -10 wk of age was used for complete blood counts (Phoenix Central Laboratory). Plasma obtained by retro-orbital bleed and centrifugation of blood at 2000  g for 5 min was frozen at -80 o C, thawed, and uPA antigen measured by ELISA (Innovative Research). Macrophage and aortic plasminogen activator activity-BM-derived macrophages were obtained as described (15) . On day 10 after plating, serumfree M199 medium was added and collected 20 hr later. Cells were counted with a hemacytometer and cell lysate protein measured with the BCA method (BioRad). Thoracic aortae were rinsed, then incubated in M199 for 4 hr and conditioned medium collected. Medium was frozen at -80 o C, thawed, and Plg activator (PA) activity measured with a chromogenic assay using human Plg (American Diagnostica) and the plasmin substrate S-2251 (Diapharma) (14) . PA activity measured in tissues from SR-uPA +/0 mice is Plg-dependent (14) . RNA extraction, purification and quantificationSix SR-uPA +/0 and 6 nontransgenic mice (all Apoe -/-) were fed the Western diet from 5 -15 wk of age, then injected intraperitoneally with thioglycollate (13) . Peritoneal macrophages were harvested in ice-cold PBS 5 d later, centrifuged (300  g for 5 min), resuspended in DMEM without phenol red (GIBCO) and plated onto tissue culture dishes. After 2 h, nonadherent cells were removed and attached cells harvested using Trizol Reagent (Invitrogen). Total RNA was extracted and purified using Total RNA PureLink Micro-to-Midi Total RNA Purification System (Invitrogen) and quantified using a Nanodrop spectrophotometer (Thermo Scientific). RNA integrity was analyzed using Agilent 2010 Bioanalyzer, the RNA integrity number for all samples was 8.9 -9.7 with the majority > 9.5. Trimmed mean intensities for each bead type were reported by the Illumina BeadArray software. For our initial analysis, the intensities were imported into R (v2.5.0) and processed using several BioConductor packages (www.bioconductor.org). Signals were normalized using the quantile normalization function of the AFFY package (26) . Hybridization control probes showed appropriate intensities and indicated no problems with RNA quality or hybridization in any of the arrays. Differential expression between groups was determined using the linear model and empirical Bayes methods in the limma package (27). All P values were corrected for multiple hypothesis testing using the method of Benjamini and Hochberg and a false discovery rate of 0.05 (28) . Gene annotations were taken from the illuminaMousev1 annotation package, which assigns gene symbols to probes that have a RefSeq identifier.
Gene ontology (GO) term over-representation analysis was performed with GOstat (29) using RefSeq identifiers and the Mouse Genome Informatics database (www.informatics.jax.org). For each GO term, a P value was calculated (using Fisher's exact test) to represent the probability that random distribution could account for the number of times this term appears in the tested group relative to the reference group (all genes on the array). Correction for multiple testing was carried out using the Benjamini and Hochberg algorithm (28) . Gene set enrichment analysis (GSEA) (30) , was also used to discover sets of genes that were regulated in association with uPA overexpression. The algorithm was implemented using the Babelomics website (31) and KEGG mouse pathway gene sets (www.genome.jp/kegg). An enrichment score was calculated for each pathway and normalized for the size of the gene set. Permutation analysis within gene sets was used to determine P values. A false discovery rate q-value (FDR) was generated by comparing the enrichment scores for individual gene sets against the permuted values and against the enrichment scores of all the gene sets.
For added confidence, we reanalyzed the gene array data independently. Probe-level intensities were quantile normalized using the preprocessCore package in BioConductor. Of the 24,611 probes on the BeadArray chip, 21,279 probes were successfully mapped to one or more mouse UniGene clusters, using the illuminaMousev1p1 software package in BioConductor. For each mouse gene probe, a twotailed t-test was used to generate a P value for differential log 2 intensity between the SR-uPA +/0 and nontransgenic samples. The log 2 of the ratio of the average intensity of the SR-uPA +/0 samples to the average intensity in the nontransgenic samples was also computed for each probe. Probes were selected that had an absolute log 2 ratio greater than 0.6 (approximately 1.5-fold), and a P value less than 0.05. This method was used in order to preferentially identify genes for which differential expression between the sample groups was large enough that differential protein expression between the groups is probable. Pathway-level analysis using MetaCoreTo identify pathways that may be activated or inhibited in macrophages by urokinase overexpression, the transcriptional profiling data were analyzed using the MetaCore software program from GeneGo (www.genego.com). Proteins encoded by genes differentially expressed in SR-uPA +/0 macrophages were extended into protein networks of up to 50 molecules based on protein-protein, protein-metabolite, and protein-DNA interactions from a large interaction database curated from the molecular biology literature. Networks were constructed using a shortest paths algorithm, based on two factors: (i) relative enrichment in the SR-uPA +/0 vs nontransgenic samples; and (ii) degree of overlap of networks with canonical pathways. The resulting ranked networks were analyzed for enrichment of biological process and molecular function annotations.
For this enrichment test gene annotations were obtained from the built-in database in MetaCore, and P values were obtained using the hypergeometric distribution. Gene function/pathway enrichment analysis-To identify groups of Gene Ontology functional annotations and molecular pathway annotations that are enriched within the upregulated and downregulated gene sets, the gene lists were analyzed using the Web-based gene annotation software program DAVID (32, 33) . This analysis identifies pathway and gene functional annotations that are enriched within either of the two sample groups relative to their genome-wide average frequencies. Enriched annotations were then clustered by similarity, and the resulting clusters were ordered based on the median of the enrichment P value (Fisher's exact test) for all of the annotations within a cluster. Transcription factor enrichment analysis of differentially expressed genes-Promoters of the differentially expressed genes were analyzed to identify transcription factors that were enriched within the set of differentially expressed genes (analyzed by MetaCore), or that have known binding-site motifs that are over-represented within the gene promoters compared to the expected frequencies of such motifs within promoters of randomly selected genes (analyzed using the web tool oPOSSUM) (34), using Fisher's exact test for significance testing. Western Blotting-Apo A-I was detected by Western analysis of extracts of aortae of 3 -4-moold SR-uPA +/0 Apoe -/-mice (either Plg +/+ or Plg -/-; n = 5 each). Western analysis of uPA in these same extracts was reported earlier (15) . S100A9 was detected by Western analysis of extracts of peritoneal macrophages of 10-wk-old SR-uPA
and nontransgenic mice (both Apoe -/-). These macrophages were obtained exactly as described above for the microarray study. Either 30 g (for the apo A-I blots) or 15 g (for the S100A9 blots) of protein were separated by SDS/PAGE and transferred to PVDF membranes (15) . Apo A-I was detected with a rabbit antibody to mouse apo E that also reacts with apo A-I [1:1000; reference (35) ], and bound antibody was detected with peroxidase-conjugated anti-rabbit IgG (1:10,000, Santa Cruz). S100A9 was detected using a goat antibody to mouse S100A9 (1:1000, R&D Systems), and peroxidase-conjugated anti-goat IgG (1:10,000, Rockland). To control for protein loading, membranes were stripped and re-probed with a mouse monoclonal antibody to GAPDH (1:7,000; Ambion). Quantitative reverse transcriptase-mediated (qRT) PCR-The same macrophage RNA samples used for the array studies were used for qRT-PCR to measure mRNA encoding S100A8, S100A9, and CX3CR1 (for primer and probe sequences see Supplementary Table 1 ). Reaction and thermal cycling conditions were as described (14) . RNA levels were normalized to GAPDH expression in the same sample, also determined by qRT-PCR (14) . S100A8 and S100A9 mRNA levels were also measured by qRT-PCR of RNA extracted from aortae of SR-uPA +/0 and nontransgenic mice (both Apoe -/-and Ldlr -/-) and from aortae of nontransgenic Apoe -/-recipients of SR-uPA
Apoe -/-or nontransgenic Apoe -/-bone marrow (14) . Regulation of macrophage S100A9 expression in vitro-Peritoneal macrophages were isolated from SR-uPA +/0 and nontransgenic Apoe -/-mice as described above, centrifuged (300  g for 5 min), resuspended in DMEM (GIBCO) and plated onto 100-mm tissue culture dishes at a density of 10 7 cells/plate. After 2 hr, nonadherent cells were removed and 10 ml fresh DMEM added. Conditioned medium was collected 48 hr later and used immediately to treat nontransgenic macrophages that had been plated in 6-well plates 2 hr earlier (1  10 6 cells/well; 1 ml conditioned medium/well). Some macrophages were treated with DMEM only as an additional control. To test whether Plg activation was sufficient to upregulate S100A9, macrophages were also treated with DMEM + plasmin (Haematologic Technologies) or with nontransgenic conditioned medium + plasmin (100 nM, a concentration at which plasmin activates signaling in both endothelial and dendritic cells) (36, 37) . After 6 hr, the medium was aspirated and the treated macrophages were washed twice with PBS to remove any cells or debris that might have been carried over with the conditioned medium. Macrophage RNA was extracted with Trizol (Invitrogen), quantified as described above, and S100A9 and GAPDH mRNA measured by qRT-PCR. Statistical methods-Data are mean ± SD except as indicated. Groups were compared with the unpaired t test or with the Mann-Whitney ranksum test for non-normally distributed data or when group variances were unequal. Two-way ANOVA on ranks was used to discern separate effects of the SR-uPA transgene and uPAR and to test for possible interactions between these two factors in determining the extent of atherosclerosis, aortic root dilation, and proximal coronary artery stenosis in Ldlr -/-mice (38) . The raw data were rank-transformed before analysis by 2-way ANOVA to satisfy the requirement of the test for normally distributed data. These tests were all carried out with the SigmaStat program (Systat Software). The microarray data were analyzed separately using the "R" statistical environment and limma analysis (27), and as described above.
RESULTS

Expression of the SR-uPA transgene in 15-wk-old Ldlr
-/-mice. We bred the SR-uPA transgene into the Ldlr -/-background, fed the mice a western diet from 5 until 15 wk of age, and measured PA activity in medium conditioned by either bone marrow-derived macrophages or thoracic aortae of nontransgenic and SR-uPA
Ldlr -/-mice. PA activity was increased in medium conditioned by SR-uPA +/0 macrophages ( Fig. 1A ; P < 0.001). However, PA activity was not significantly increased in medium conditioned by SR-uPA +/0 aortae ( Fig. 1B ; P = 0.5). Expression of the SR-uPA +/0 transgene did not significantly affect plasma cholesterol, triglycerides, or FPLC profiles of Ldlr -/-mice (Table 1 and Supplementary Fig. 1 ). Similarly, peripheral blood monocyte and percent monocyte counts were not affected by the SR-uPA transgene (Table  1) .
Macrophage -/-). The mice were fed a highfat diet beginning at 5 wk of age and atherosclerosis was assessed 20 wk later.
Neither Plaur genotype nor the SR-uPA transgene affected either peripheral blood monocyte counts or percent peripheral blood monocytes in these 25-wk-old mice (Table 2) . Total plasma cholesterol was unaffected by the SR-uPA transgene in Plaur +/+ mice; however, in Plaur -/-mice plasma cholesterol was modestly increased in SR-uPA +/0 versus nontransgenic mice (Table 2 ; P = 0.02). Nevertheless, FPLC profiles of plasma lipids were similar in all 4 groups ( Supplementary Fig. 2 ) as were the plasma concentrations of LDL, HDL, and triglycerides (Table 2 and Supplementary Fig. 2 (Fig. 3A) . Elevated PA activity was present in medium conditioned by bone marrow-derived macrophages of both SR-uPA +/0 Plaur +/+ and SR-uPA +/0 Plaur -/-mice (all 25-wk-old; Fig. 3B ). In contrast to results obtained with aortae of 15-wk-old mice (Fig. 1B) , PA activity was also significantly elevated in medium conditioned by aortae of 25-wk-old SR-uPA +/0 mice (Fig. 3C) . Plaur genotype did not significantly affect plasma uPA antigen or secreted PA activity (Fig. 3 A-C) .
uPA-accelerated atherosclerosis is timedependent and does not require uPAR; uPAR is atherogenic. In 25-wk-old Plaur +/+ mice, the SRuPA transgene increased aortic root intimal lesion area by 2.3-fold ( Fig. 4; 1 (Table 2 ). In 25-wk-old Plaur -/-mice, the SR-uPA transgene increased aortic root intimal area by 2.1-fold ( Fig. 4; 1 Fig. 5 ; P < 0.01 for both).
This experiment also revealed a role for uPAR in atherogenesis. This role was most apparent in the nontransgenic mice, in which absence of uPAR reduced both aortic root intimal lesion area and Sudan IV-positive aortic surface coverage (Figs. 4 -5 ; P = 0.04 for both). In SR-uPA +/0 mice, absence of uPAR reduced aortic root intimal lesion area ( Fig. 4 ; P = 0.02) but did not significantly change aortic surface coverage by Sudan IV-positive lesions ( Fig. 5 ; P = 0.3). 2-way ANOVA (which analyzes data from all 4 groups; see Statistical methods) revealed: 1) overall significant effects of the SR-uPA transgene (independently of uPAR) on both aortic root intimal area and aortic surface atherosclerosis (P < 0.001); and 2) overall significant effects of uPAR genotype (independently of the SR-uPA transgene) on both aortic root intimal area (P = 0.003) and aortic surface atherosclerosis (P = 0.01).
Both Table 2 and Supplementary Fig. 3 ).
Two-way ANOVA confirmed significant, independent effects of both the SR-uPA transgene and uPAR on coronary stenosis severity (P ≤ 0.005 for both).
Apo A-I protein is not degraded in aortae of SR-uPA mice. We next focused on identifying the molecular mechanisms through which uPA, acting via Plg (15) Supplementary Fig. 4) . Table 2 ). S100A9 (calgranulin B) and S100A8 (calgranulin A) were the two most highly upregulated transcripts. CX3CR1, which plays a significant role in atherosclerosis (41) , was also upregulated in SR-uPA +/0 macrophages. Several collagens were among the most highly downregulated transcripts. GOstat analysis of the up-regulated genes revealed 11 overrepresented GO terms (P = 0.04 -0.05); however, these were represented by only 1 -2 transcripts each (Supplementary Table 3 and data not shown).
Analysis of differential gene expression in SR-
GOstat analysis of downregulated transcripts revealed 19 overrepresented GO terms (P = 0.03 -4 x 10 -11 ) with 2 -26 transcripts per term (Supplementary Table 3 and data not shown). Overrepresented GO terms for which at least 5 downregulated transcripts were observed included several terms related to the extracellular matrix, cell adhesion or proteinase inhibition. GSEA revealed several sets of genes that appeared to be regulated in association with macrophage uPA overexpression (P < 0.05 with most FDR q values < 0.25; Supplementary Table 4) , including sets related to tight junctions, cell communication, ECM-receptor interaction, and regulation of actin cytoskeleton.
To help focus subsequent validation studies on the most likely candidate genes, we performed a second, independent analysis of the array data, using different normalization and statistical testing. This analysis revealed 75 probes with an absolute log 2 ratio > 0.6 (approximately 1.5-fold) and P < 0.05, including 17 with higher intensities in the SR-uPA +/0 group and 54 with lower intensities in the SR-uPA +/0 group (Supplementary Table 5 ). As before, S100A9 and S100A8 were the most highly upregulated transcripts in SRuPA +/0 macrophages. A significant (P = 0.02) upregulation of the atherogenic cytokine IL-1β (42), was detected in this analysis (Supplementary Table 2 ). Nine up-regulated genes and 34 downregulated genes were common to both lists (Supplementary Tables 2, 5) .
Pathway-level analysis using MetaCore. We used the MetaCore network analysis software to identify protein interaction networks that are enriched for molecules differentially expressed in SR-uPA +/0 versus nontransgenic macrophages. One network (Supplementary Fig. 5 ) was identified that connected S100A8 and S100A9 to pathogen-associated and damage-associated molecular pattern receptors toll-like receptor 4 (TLR4) and the receptor for advanced glycation end products (RAGE), and connected these receptors to two transcription factors associated with macrophage activation, NF-kB and c-jun, a component of AP-1.
Gene function / pathway enrichment analysis. Analysis of the microarray data with DAVID (Supplementary Table 8 ). These factors include: the AP-1 components c-fos and c-jun; the NF-kB components c-Rel, RelA, and NF-kB1; C/EBPbeta; Sp1; and NFYA. RelA, Sp1, and NF-kB1 were identified by both approaches.
qRT-PCR reveals upregulation of S100A9 and S100A8 mRNA in SR-uPA +/0 macrophages and aortae. The significant upregulation of S100A9 and S100A8 mRNA was perhaps the most interesting quantitative result from the microarray experiments. We further tested this finding by qRT-PCR performed on the macrophage RNA samples used for the array study. This analysis confirmed significantly increased S100A9 and S100A8 mRNA in SR-uPA +/0 versus nontransgenic peritoneal macrophages (P ≤ 0.015 for both; Fig. 6A, B) . In contrast, qRT-PCR of CX3CR1 mRNA showed only a trend towards increased mRNA in SR-uPA +/0 macrophages (P = 0.1; data not shown). To investigate whether S100A9/A8 mRNA were also upregulated in atherosclerotic aortae of SR-uPA +/0 mice (and therefore would be more likely to contribute to atherogenesis), we repeated the qRT-PCR of S100A9 and S100A8 using aortic RNA from 45-wk-old nontransgenic Apoe -/-recipients of SRuPA +/0 or nontransgenic bone marrow (available from a previous study) (16) . Both transcripts were significantly more abundant in aortae of SRuPA +/0 bone marrow recipients (P ≤ 0.004 for both; Fig. 6C, D) . S100A9 and S100A8 mRNA were also elevated in aortae of germ line transgenic SR-uPA +/0 Apoe -/-versus nontransgenic Apoe -/-mice (P = 0.057 for both; Fig. 6E, F) . The magnitude of increased S100A8 and A9 mRNA (i.e., the relative increases in the medians of the SR-uPA +/0 groups compared to the medians of the corresponding SR-uPA 0/0 groups in Fig. 6 ) range from 2.2 -6.4-fold. This degree of increased S100A8 and S100A9 expression is numerically larger than the magnitude of increased macrophage accumulation in these aortae [1.7 -2.0-fold; see primary data in references (15, 16) ], which supports the hypothesis that increased S100A8 and A9 expression in SR-uPA +/0 aortae is not due simply to an increase in aortic wall macrophages.
Upregulation of macrophage S100A9 protein in association with uPA overexpression in vivo and in vitro. To test whether uPA overexpression also increases S100A9 protein, we performed Western analysis of extracts of peritoneal macrophages of SR-uPA +/0 and nontransgenic Apoe -/-mice. We found 40% more S100A9 protein in SR-uPA +/0 than in nontransgenic macrophages (1.4  0.29 versus 1.0  0.21 AU; P = 0.01; Figs. 7A, B) . To further investigate whether macrophage overexpression of uPA is sufficient to upregulate expression of S100A9, we harvested media conditioned by either SR-uPA +/0 or nontransgenic peritoneal macrophages and added these conditioned media (or DMEM alone) to nontransgenic macrophages.
We used macrophage-conditioned medium for these experiments rather than purified uPA because uPA overexpression in macrophages has biologically important downstream effects (including activation of both plasminogen and matrix metalloproteinases) (16) that would not be accurately modeled simply by addition of uPA. Medium conditioned by SR-uPA +/0 macrophages upregulated S100A9 mRNA expression compared to both of the control groups (P ≤ 0.04 for both; Fig. 8 ). Increased S100A9 mRNA was not due solely to plasminogen activation because plasmin (100 nM) in either DMEM alone or in nontransgenic conditioned medium did not upregulate S100A9 expression in nontransgenic macrophages (S100A9 expression = 93 -98% of DMEM alone values; n = 4 for both; data not shown).
DISCUSSION
To further elucidate mechanisms of uPA/Plgaccelerated atherosclerosis, we bred the SR-uPA transgene into the Ldlr -/-and Plaur -/-backgrounds and measured atherosclerosis and aortic dimensions in SR-uPA +/0 mice and nontransgenic littermate controls. We also performed microarray studies on macrophages of SR-uPA +/0 and nontransgenic Apoe -/-mice. Our major findings are: i) macrophage-expressed uPA accelerates atherosclerosis and causes aortic root dilation in the Ldlr -/-background; ii) macrophage-expressed uPA does not increase lesion initiation, but instead accelerates growth of established lesions; iii) vascular pathologies that result from macrophage uPA overexpression are largely, if not completely, independent of uPAR; iv) uPAR is atherogenic and also contributes to aortic dilation; v) uPAoverexpressing macrophages express increased S100A8 and S100A9 and release a soluble factor that upregulates S100A9 expression in nontransgenic macrophages; vi) S100A8 and S100A9 expression are increased in aortae of mice with macrophage-specific uPA overexpression; and vii) global gene expression analysis suggests that altered cell migration and cell-matrix interactions may contribute to uPA/Plg-accelerated atherosclerosis.
We found that SR-uPA
Ldlr -/-mice developed the same vascular disease phenotypes we described previously in SR-uPA +/0 Apoe -/-mice (13), including accelerated aortic atherosclerosis, severe proximal coronary stenoses, aortic root dilation, and premature sudden death (Figs. 2, 4, 5 ; Tables 1-2 ; and data not shown). Reproduction of these phenotypes in a second mouse model strengthens the conclusion that macrophage-expressed uPA is atherogenic and causes aortic dilation. Notably, however, both aortic surface atherosclerosis and aortic root dilation developed more slowly in SR-uPA (Table  1) suggests that macrophage overexpression of uPA does not increase lesion initiation but instead affects lesion progression. A preferential effect of uPA on lesion progression is also supported by our finding of more substantially accelerated atherosclerosis in aortic roots of 25-wk-old versus 15-wk-old SR-uPA
Ldlr
-/-mice ( Supplementary Fig 6A) and by the equivalent Sudan IV stained area of aortae of 15-wk-old SR-uPA +/0 and nontransgenic mice compared to the significantly increased Sudan IV stained area of aortae of 25-wk-old SR-uPA +/0 versus nontransgenic mice (Supplementary Fig.  6B ). An effect of uPA/Plg on atherosclerosis progression versus initiation is consistent with the expression pattern of the SR-uPA transgene, which is transcribed in macrophages (within the lesions) but not in peripheral blood monocytes (13, 14) .
Our finding of accelerated lipid accumulation in early lesions of SR-uPA +/0 versus nontransgenic Ldlr -/-mice (Table 1) provides another clue to the mechanisms of uPA/Plgaccelerated atherosclerosis, suggesting that increased artery wall Plg activation enhances lipid entry, retards lipid efflux, or both. The enhanced lipid accumulation does not appear to be due to uPA/Plg-mediated proteolysis of apo A-I, which would interfere with reverse cholesterol transport (39, 40) (Supplementary Fig. 4) . Future work will be aimed at identifying the mechanisms of uPA/Plg-mediated lipid accumulation. These mechanisms could include increased artery wall permeability (due to uPA/Plg-stimulated proteolysis of either endothelial basement membrane or tight junction-forming proteins) or via S100A8/A9-mediated increases in artery wall permeability (see below).
Alternatively, proteolysis of vascular matrix proteins could enhance lipid retention by exposing vessel wall neoepitopes that have lipoprotein-binding activity (46) .
We also investigated a role for uPAR both in uPA/Plg-accelerated atherosclerosis and independently of uPA expression. Considerable published data suggest that uPAR is atherogenic. In humans, uPAR is expressed in atherosclerotic plaques in direct relation to lesion severity (7), and patients with acute myocardial infarction have increased expression of uPAR on their peripheral blood monocytes (47) . In vitro studies reveal roles for uPAR in cell adhesion, migration, lipid accumulation, and oxidative stress (18, 48, 49) , and in vivo animal studies demonstrate roles for uPAR in platelet adhesion to activated endothelium, foam cell formation, and macrophage accumulation in the artery wall (50) (51) (52) . uPAR also dramatically increases the efficiency of Plg activation by uPA (17) . All of these activities would promote atherogenesis; however, a role for uPAR in modulating atherosclerotic lesion growth has not previously been tested experimentally.
Here we found that genetic deletion of uPAR in nontransgenic Ldlr -/-mice decreased aortic root and aortic surface atherosclerosis and inhibited both aortic root dilation and the development of coronary stenoses. Deletion of uPAR in SRuPA
Ldlr -/-mice decreased aortic root atherosclerosis, coronary artery stenosis severity, and aortic dilation similarly as in nontransgenic mice. These data suggest that uPAR itself makes modest contributions to atherogenesis and aneurysm formation but that-unlike Plg (15)-it plays at most a minor role in uPA-accelerated atherosclerosis. The pathways through which uPAR contributes to atherogenesis and aneurysm formation-including whether this contribution depends on uPA-uPAR binding (48)-are not addressed here.
Microarray analysis revealed significant upregulation of S100A8 and A9 in macrophages, qRT-PCR confirmed this finding in macrophages as well as aortae of SR-uPA mice and Western blotting confirmed upregulation of S100A9 protein in SR-uPA macrophages (Figs. 6 and 7) . A causal connection between macrophage uPA overexpression and S100A9 upregulation is also supported by ex vivo experiments (Fig. 8) , although the molecular pathways that lead from uPA expression to S100A8/A9 upregulation remain to be defined. S100A8/A9 are excellent candidate mediators of accelerated atherosclerosis in SR-uPA mice and of uPA/Plg-mediated atherogenesis in humans because they are present in human and mouse lesions and are atherogenic in mice (53) (54) (55) . S100A8/A9 potentially accelerate atherosclerosis via chemoattractant and proinflammatory activities that include binding to the receptor for advanced glycosylated end products (RAGE) and toll-like receptor 4 (TLR4), activation of NF-kB, and upregulation of the adhesion molecule CD11b in circulating monocytes (56) (57) (58) . A recent study, however, suggested that atherogenic effects of S100A8/A9 may result from expression in non-hematopoietic cells, including endothelial cells (59) . S100A8/A9 can impair endothelial integrity by disrupting cellcell contacts and promoting apoptosis (60) , actions that would likely increase lipid entry to the artery wall and could facilitate monocyte entry as well. Therefore S100A8/A9 could mediate enhanced accumulation of both lipids and macrophages in lesions of SR-uPA +/0 mice. S100A8/A9 are also associated with plaque rupture in both humans and diabetic mice (53, 61) , and older SR-uPA +/0 mice have significantly increased plaque rupture (16) . It will be interesting to generate SR-uPA +/0 mice that are deficient in S100A8/A9, and test whether accelerated atherosclerosis and plaque rupture in SR-uPA +/0 mice are dependent on S100A8/A9. In addition to identifying upregulation of S100A8/A9, the microarray studies provide insights into other pathways through which uPA overexpression may yield a more atherogenic macrophage. These pathways include increased cell adhesion and cell motility (suggested by GO, GSEA, and DAVID terms such as taxis, chemotaxis, ECM-receptor interaction, regulation of actin cytoskeleton, response to external stimuli, and locomotory behavior), and altered extracellular proteolysis (suggested by terms such as proteinase inhibition, extracellular matrix, and extracellular space).
Notably, an unbiased network constructed from the array data ( Supplementary Fig. 5 ) included S100A8/A9, the pattern recognition receptors TLR4 and RAGE, and transcription factors (AP-1 and NF-kB) that regulate several genes that are differentially regulated in SR-uPA +/0 macrophages. These molecules are all associated with inflammatory diseases, including atherosclerosis. Taken together, our data suggest a multifaceted model of pathways through which macrophage uPA expression could accelerate atherosclerosis (Fig.  9) . Experiments that test this model and pinpoint the pathways through which macrophageexpressed uPA and Plg act to accelerate atherosclerosis could reveal new targets for atheroprotective therapies. FIGURE 6. S100A9 and S100A8 mRNA in macrophages and aortae of Apoe -/-mice. Total RNA was extracted from peritoneal macrophages or aortae; S100A9 and S100A8 mRNA were measured by qRT-PCR, with normalization to GAPDH mRNA. A, B. S100A9 and S100A8 mRNA in peritoneal macrophages from SR-uPA 0/0 or SR-uPA +/0 mice. C, D. S100A9 and S100A8 mRNA in aortae of SRuPA 0/0 recipients of either SR-uPA 0/0 or SR-uPA +/0 bone marrow. E, F. S100A9 and S100A8 mRNA in aortae of SR-uPA 0/0 or SR-uPA +/0 mice. Data points are individual mice; bars are group medians. P values are from Mann-Whitney tests. ). Mice were fed a high-fat diet from 5 until 10 wks of age, peritoneal macrophages harvested, protein extracted, and analyzed. A. Western blot of macrophage extracts from individual nontransgenic and SR-uPA +/0 mice (upper panel). The blot was stripped and reprobed to detect GAPDH (lower panel). B. Densities of the S100A9 bands in A, and from 3 additional mice in each group, normalized to the corresponding GAPDH densities. Data points are from individual mice from 2 independent experiments; bars are group means, with the mean of the nontransgenic group in each experiment set to 1.0. P value is from t-test. FIGURE 8. S100A9 mRNA, measured in nontransgenic macrophages. Peritoneal macrophages harvested from nontransgenic Apoe -/-mice were treated for 6 hr with DMEM alone, or with DMEM previously conditioned by SR-uPA +/0 or SR-uPA 0/0 Apoe -/-macrophages. RNA was extracted and S100A9 and GAPDH mRNA measured by qRT-PCR. Data are means ± SEM of three independent experiments performed with a total of 4 -8 wells of cultured macrophages for each group. The mean of the DMEM-only group in each experiment was set to 1.0. P values are from t-tests. FIGURE 9. Model of pathways through which macrophage uPA expression could accelerate atherosclerosis. Model is constructed based on data from the present study and others showing that macrophage overexpression of uPA promotes early lesion lipid accumulation as well as later lesion macrophage accumulation, increases macrophage migration, enhances vascular MMP activity, accelerates lesion progression, and stimulates macrophage S100A8/A9 expression (13-16). 1) uPA-expressing macrophages begin to accumulate within an early lesion 2) These macrophages secrete S100A8/A9 ), and were either wild-type or null for the uPA receptor (Plaur +/+ or -/-). All mice were fed a high-fat diet from 5 -25 weeks of age. n = number of mice in each group. Data are mean ± SD except for % coronary stenosis which is ± SEM. P values are for comparison of nontransgenic and transgenic mice within each Plaur genotype and are from t-tests except for peripheral blood monocytes, triglycerides, ORO positive area, and coronary stenosis (Mann-Whitney tests). 
Plaur
